Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma

Abstract EN

Background.

The incidence of lung cancer is the highest of all cancers, and it has the highest death rate.

Lung adenocarcinoma (LUAD) is a major type of lung cancer.

This study is aimed at identifying the prognostic value of immune-related long noncoding RNAs (lncRNAs) in LUAD.

Materials and Methods.

Gene expression profiles and the corresponding clinicopathological features of LUAD patients were obtained from The Cancer Genome Atlas (TCGA).

The least absolute shrinkage and selection operator (LASSO) Cox regression algorithm was performed on the prognostic immune-related lncRNAs to calculate the risk scores, and a risk signature was constructed.

Survival analysis was performed to assess the prognostic value of the risk signature.

A nomogram was also constructed based on the clinicopathological features and risk signature.

Results.

A total of 437 LUAD patients with gene expression data and clinicopathological features were obtained in this study, which was considered the combination set.

They were randomly and equally divided into a training set and a validation set.

Seven immune-related lncRNAs (AC092794.1, AL034397.3, AC069023.1, AP000695.1, AC091057.1, HLA-DQB1-AS1, and HSPC324) were identified and used to construct a risk signature.

The patients were divided into the low- and high-risk groups based on the median risk score of -0.04074.

Survival analysis suggested that patients in the low-risk group had a longer overall survival (OS) than those in the high-risk group (p=1.478e−02).

A nomogram was built that could predict the 1-, 3-, and 5-year survival rates of LUAD patients (C-index of the nomogram was 0.755, and the AUCs for the 1-, 3-, and 5-year survivals were 0.826, 0.719, and 0.724, respectively).

The validation and combination sets confirmed these results.

Conclusion.

Our study identified seven novel immune-related lncRNAs and generated a risk signature, as well as a nomogram, that could predict the prognosis of LUAD patients.